PHASTAR wins prestigious Queens Award for Enterprise

PHASTAR named as winners of prestigious Queens Award for Enterprise

PHASTAR is delighted to be announced today as winners of the highly coveted Queens Award for Enterprise, in the International Trade category!

PHASTAR’s win was down to its excellence in international trade and its exponential growth from a one-person operation in 2007, to a global CRO with offices in four continents within the space of one decade. PHASTAR’s reputation as a quality provider of statistics, programming and data science services to the pharmaceutical and biotechnology industries now sees it as one of the top 10 data focused CROs worldwide.

The Queens Award, now in its 53rd year, focuses on outstanding achievement by UK businesses in several categories including innovation, international trade and sustainable development, with winning companies invited to a royal reception in Buckingham Palace and receiving an official grant of appointment from one of The Queen’s representatives.

Commenting on the win, Kevin Kane, PHASTAR’s Founder and CEO, stated: “I am so proud of what we as a company have achieved in our ten years in business. PHASTAR’s impressive year on year growth is down to the exceptional quality of our people, our culture and our reputation with our customers. Being announced as winners of the impressive Queens Award for Enterprise is a huge accolade for us and spurs on our ambitious future international growth plans. As founder and CEO of PHASTAR, I am incredibly honoured to take a UK company and build an international business that continues to grow in a highly competitive market”.

PHASTAR has recently increased in foothold in the US with the opening of its Boston office and will continue to diversify its business locations with a keen interest in opening a base in Japan and West Coast US in the next 12 months. PHASTAR currently has ten offices across four continents and its ambitious future growth plans includes doubling its staff numbers in the next four years.

PHASTAR celebrates opening of new Boston office!

PHASTAR's Boston office has officially opened! The opening represents an important milestone in PHASTAR's history as its second office in the US and its first in the important Life Science Corridor of Massachusetts.

Commenting on the new Boston location, PHASTAR’s CEO Kevin Kane stated: “this is a huge step forward for PHASTAR and it demonstrates our determination to grow significantly over the next five years. We are delighted to be amongst the 1,000+ biotech and pharma companies which make up Boston’s Life Science hub”.

PHASTAR's newly appointed Director of Biostatistics, Paul Stark, will head up the Boston site. Paul brings with him over 20 years of clinical trials experience and has served as a director for more than 13 years at CROs and in medical centers and academic settings. Paul has applied statistics to medical devices and drugs for cardiology, nephrology, oral health, environmental health and oncology and has also authored and co-authored more than 65 manuscripts in peer-reviewed journals.

Interested in joining PHASTAR? Contact This email address is being protected from spambots. You need JavaScript enabled to view it. to find out more about our live roles.

Interested in finding out more about how PHASTAR can help your company? Contact This email address is being protected from spambots. You need JavaScript enabled to view it..

 

PHASTAR nominated for 2018 SCRIP Award!

PHASTAR: SCRIP 2018 Finalist

PHASTAR is delighted to have been shortlisted for the 2018 SCRIP Award in the category: Best Contract Research Organization – Specialist Provider. For the third year in succession, PHASTAR has been recognised for its success in delivering high quality statistical consulting, clinical trial reporting and data management.

Now in its 14th year, the Scrip Awards has provided the industry with an opportunity to acknowledge its highest achievers with trophies covering a range of activities, from new drug launches, to innovative deals, outsourcing and fundraising.

We look forward to the awards ceremony, which will be held on the 28th November 2018 in London.

More information can be found here.

PHASTAR presents webinar on Medrio

On Tuesday 24th July 2018, PHASTAR presented a webinar on the topic 'Efficiencies when delivering a quality database'. The presenters were Sheelagh Aird, Head of Clinical Data Operations and Gillian Childs, Principal Data Coordinator. The webinar, hosted by X-talks and Medrio, demonstrated the importance of controlling the quality of a database right from study set-up.

The webinar introduced the use of the Data Quality Plan and the concept of identifying risk items and processes, defining quality, how quality is assessed and how it can be achieved. The presenters discussed how to select key personnel for ensuring quality and the processes to action and report on findings identified at data quality review timepoints.

The presenters described how the Data Management team at PHASTAR use Medrio tools and functionality to efficiently monitor data quality within the database. At study level, the analysis of data by comparing various expected limits against observed limits allows a visual understanding of where the potential errors occur and draws focus to particular site(s) for investigation.  At site level, outlying subject data can be scrutinised for errors, making quality control more time efficient. Observation of data trends can be identified, giving an overview of which data points may not follow the trends and can be targeted for further investigation. Focus is given to data which have the highest risk where errors would have the greatest impact on the integrity and safety of the trial. 

An interactive audience poll on the frequency of use of the audit trail to monitor data quality revealed a diversity of approach from ‘Never’ to ‘Daily’.  PHASTAR’s use of the audit trail was summarised as daily during subject data review and frequently during data quality monitoring. The presenters highlighted the importance of reviewing the audit trail and its use as a tool to ensure accuracy of data and site data entry issues. 

The webinar discussed how to feed findings back to site following data quality reviews, which are performed at defined periods in accordance with the Data Quality Plan. Positive feedback as well as areas to concentrate on improvement were highlighted, especially encouraging sites to enter data as early as possible and maintain good data flow. The webinar showed various ways to measure site performance within Medrio and discussed how sites can use tools such as the Dashboard, missing data and query ageing reports to review their own efficiencies.

The early identification of issues is vital to ensure that meaningful data is collected, allowing time for sites to improve processes and for errors to be addressed. By adopting these processes, PHASTAR is able to successfully reduce timelines between last subject last visit to database lock whilst ensuring high data quality. 

The webinar was very well received with a range of questions during Q&A session including how to set expectations in early phase rare disease studies and the use of Medrio in Phase III studies. There was excellent feedback from attendees including post-webinar requests for additional information and PHASTAR’s Data Management team will be following up with further presentations and white papers.

Sign up for this free webinar at https://xtalks.com/webinars/quality-database-tools-techniques-for-a-successful-clinical-trial/

To find out more about Medrio's eClinical solutions, visit www.medrio.com.